Skip to main content

Table 2 Demographics and baseline disease characteristics of study population

From: Differential regulation of TNFα and IL-6 expression contributes to immune evasion in prostate cancer

 

No TNF use

(Group 1)

TNF use pre PCa diagnosis (Group 2)

p Value

Number

119814

390

 

Age at Dx [mean(SD)]

65.76 (8.14)

64.96 (6.85)

0.052

Less than 55

8379 (7.0%)

20 (5.1%)

0.179

55–64

49546 (41.4%)

174 (44.6%)

0.21

65–74

43316 (36.2%)

159 (40.8%)

0.066

75 and Up

18573 (15.5%)

37 (9.5%)

0.001

Race

  

 < 0.001

African American

32655 (27.3%)

56 (14.4%)

 

White

82894 (69.2%)

323 (82.8%)

 

Other

1318 (1.1%)

6 (1.5%)

 

Unknown

2947 (2.5%)

5 (1.3%)

 

T Stage 1

78899 (65.9%)

286 (73.3%)

0.002

T Stage 2

36839 (30.7%)

98 (25.1%)

0.019

T Stage 3 or 4

4075 (3.4%)

6 (1.5%)

0.059

Gleason 6

48261 (40.3%)

172 (44.1%)

0.138

Gleason 7

47878 (40.0%)

162 (41.5%)

0.56

Gleason 8 or Higher

23690 (19.8%)

56 (14.4%)

0.009

Mean pre diagnostic PSA (SD)

18.15 (71.59)

8.60 (11.99)

0.011

Median pre diagnostic PSA

6.55

5.5

 

PSA over 20 at Dx

12253 (11.4%)

23 (6.3%)

0.003

N Stage 1

1965 (1.6%)

6 (1.5%)

1

M Stage 1

4840 (4.0%)

9 (2.3%)

0.108

  1. TNF tumor necrosis factor, Dx Diagnosis, SD standard deviation, PSA prostate specific antigen